Drug and Therapeutics Bulletin 1995;33:36-37; doi:10.1136/dtb.1995.33536
Copyright © 1995 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Lansoprazole - another proton pump inhibitor

Relevant BNF section: 1.3.5

Lansoprazole (Zoton - Lederle) is a proton pump inhibitor recently licensed for the treatment of duodenal ulcer, benign gastric ulcer or reflux oesophagitis. It is structurally related to omeprazole, which has now been available in the UK for 6 years. In this article we consider the place of lansoprazole in the treatment of patients with acid-related digestive tract disorders.




This article has been cited by other articles:


Home page
 Fam PractHome page
M. I Jones, S. M Greenfield, S. Jowett, C. P Bradley, and R. Seal
Proton pump inhibitors: a study of GPs' prescribing
Fam. Pract., June 1, 2001; 18(3): 333 - 338.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1995 BMJ Publishing Group Ltd.